1,2-Dibenzoylhydrazine as a Multi-Inhibitor Compound: A Morphological and Docking Study

Area of Science:

• Medicinal Chemistry
• Computational Biology
• Drug Discovery

Background:

• Multitarget inhibitors are crucial for complex diseases.
• 1,2-dibenzoylhydrazine (DBH) is a compound with potential biological activity.
• Understanding DBH's interaction with key receptors is essential for drug design.

Purpose of the Study:

• To investigate the in silico inhibitory potential of DBH against three distinct targets: ecdysone receptor (EcR), urease, and HIV-integrase.
• To evaluate DBH as a multitarget inhibitor using molecular modeling.
• To explore the potential of DBH as a lead compound for novel therapeutic agents.

Main Methods:

• In silico analysis including molecular docking studies.
• Crystallographic structural analysis of DBH.
• Crystal morphology prediction.
• Computational evaluation of ligand-receptor interactions.

Main Results:

• DBH demonstrated excellent inhibitory potential against ecdysone receptors (EcR) and urease.
• Docking studies confirmed DBH's activity against the HIV-integrase receptor.
• The compound shows promise as a multitarget inhibitor.

Conclusions:

• DBH is a highly promising candidate for inhibiting EcR, urease, and HIV-integrase.
• DBH serves as an excellent starting lead compound for developing novel multitarget inhibitors.
• This research provides a foundation for future structure-based drug design efforts.